SHR-A1811 + adebelimab + bevacizumab

**SHR-A1811 + adebelimab + bevacizumab** is a combination therapy comprising three agents: - **SHR-A1811**, a third-generation antibody-drug conjugate (ADC) directed against HER2, designed to deliver cytotoxic payloads specifically to HER2-altered cancer cells. It has demonstrated meaningful efficacy and a favorable safety profile in pretreated or neoadjuvant settings for HER2-mutant non-small cell lung cancer (NSCLC) and HER2-positive breast cancer[1][3][7]. - **Adebelimab** is a monoclonal antibody targeting PD-1, functioning as a checkpoint inhibitor to block the immune suppressive effects mediated by the PD-1/PD-L1 pathway and promote anti-tumor immune responses (based on its class). - **Bevacizumab** is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby reducing tumor blood supply[2][8]. It is approved for various cancers, including non-small cell lung cancer, colorectal cancer, breast cancer, and others[2][4][8]. Overall, this combination targets HER2-driven tumor proliferation (SHR-A1811), suppresses tumor immune evasion (adebelimab), and inhibits angiogenesis (bevacizumab).

Brand names

Avastin

Other names

SHR-A1811SHR-A-1811SHR-A 1811adebelimabbevacizumab